, Volume 12, Issue 2, pp 139–157 | Cite as


A Review of its Use in the Diagnosis and Treatment of Children with Idiopathic Growth Hormone Deficiency
Adis Drug Evaluation



Sermorelin, a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH), is the shortest synthetic peptide with full biological activity of GHRH. Intravenous and subcutaneous sermorelin specifically stimulate growth hormone secretion from the anterior pituitary.

Hormone responses to intravenous sermorelin 1μg/kg bodyweight appear to be a rapid and relatively specific test for the diagnosis of growth hormone deficiency. False positive growth hormone responses are observed in fewer children without growth hormone deficiency after sermorelin than after other provocative tests. Adult data indicate that the combination of intravenous sermorelin and arginine is a more specific test and this merits evaluation in children with growth hormone deficiency. However, normal growth hormone responses to intravenous sermorelin cannot exclude growth hormone deficiency due to a hypothalamic deficit: subnormal growth hormone response to other provocative tests is needed to confirm the presence of disease in these patients.

Limited data indicate that once daily subcutaneous sermorelin 30 μg/kg bodyweight given at bedtime is effective in treating some prepubertal children with idiopathic growth hormone deficiency. Significant increases in height velocity were sustained during 12 months’ treatment with sermorelin and data in a few children suggest the effect is maintained for 36 months of continued treatment. Sermorelin induced catch-up growth in the majority of growth hormone-deficient children. Slow growing, shorter children with delayed bone and height age appear to have a good response to treatment with sermorelin. The effect of long term treatment with once daily subcutaneous sermorelin 30 μg/kg bodyweight on final adult height is yet to be determined.

The effects of the recommended dosage of sermorelin have not been directly compared with those of somatropin. However, increases in height velocity from baseline values with subcutaneous sermorelin 30 μg/kg bodyweight per day, given as continuous infusion or as 3 divided doses, were less than those in children receiving once daily subcutaneous somatropin 30 μg/kg bodyweight.

Intravenous single dose and repeated once daily subcutaneous doses of sermorelin are well tolerated. Transient facial flushing and pain at injection site were the most commonly reported adverse events.

Conclusions: Sermorelin is a well tolerated analogue of GHRH which is suitable for use as a provocative test of growth hormone deficiency when given as a single intravenous 1 μg/kg bodyweight dose in conjunction with conventional tests. Limited data suggest that once daily subcutaneous sermorelin 30 μg/kg bodyweight is effective in promoting growth in some prepubertal children with idiopathic growth hormone deficiency.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Grossman A, Savage MO, Besser GM. Growth hormone releasing hormone. Clin Endocrinol Metab 1986 Aug; 15: 607–27PubMedCrossRefGoogle Scholar
  2. 2.
    First approval of Geref as therapeutic. Marketletter 1997 Oct 13; 24: 20Google Scholar
  3. 3.
    Bullock J, Boyle III J, Wang MB, editors. National medical series for independent study: physiology. 3rd ed. New Delhi: B.I. Waverly Private Limited, 1995Google Scholar
  4. 4.
    Baumann G. Growth hormone heterogeneity: genes, isohormones, variants, and binding proteins. Endocr Rev 1991; 12: 424–49PubMedCrossRefGoogle Scholar
  5. 5.
    Ishikawa M, Yokoya S, Tachibana K, et al. Serum levels of 20-kilodalton human growth hormone (GH) are parallel those of 22-kilodalton human GH in normal and short children. J Clin Endocrinol Metab 1999; 84: 98–104PubMedCrossRefGoogle Scholar
  6. 6.
    Boguszewski CL, Jansson C, Boguszewski MCS, et al. Increased proportion of circulating non-22-kilodalton growth hormone isoforms in short children: a possible mechanism for growth failure. J Clin Endocrinol Metab 1997; 82: 2944–9PubMedCrossRefGoogle Scholar
  7. 7.
    Laron Z. Growth hormone secretagogues: clinical experience and therapeutic potential. Drugs 1995; 50: 595–601PubMedCrossRefGoogle Scholar
  8. 8.
    Arvat E, Camanni F, Ghigo E. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans. Acta Paediatr 1997 Suppl. 423: 92–6Google Scholar
  9. 9.
    Ghigo E, Arvat E, Camanni F. Orally active growth hormone secretagogues: state of the art and clinical perspectives. Ann Med 1998; 30: 159–68PubMedCrossRefGoogle Scholar
  10. 10.
    Ghigo E, Arvat E, Valente F, et al. Arginine reinstates the somatotrope responsiveness to intermittent growth hormone-releasing hormone administration in normal adults. Neuroendocrinology 1991; 54(3): 291–4PubMedCrossRefGoogle Scholar
  11. 11.
    Giustina A, Bossoni S, Bodini C, et al. The role of cholinergic tone in modulating the growth hormone response to growth hormone-releasing hormone in normal man. Metab Clin Exp 1991; 40(5): 519–23PubMedCrossRefGoogle Scholar
  12. 12.
    Cassorla F, Mericq V, Garcia H, et al. The effects of β1 -adrenergic blockade on the growth response to growth hormone (GH)-releasing hormone therapy in GH-deficient children. J Clin Endocrinol Metab 1995; 80(10): 2997–3001PubMedCrossRefGoogle Scholar
  13. 13.
    Delitala G, Palermo M, Ross R, et al. Dopaminergic and cholinergic influences on the growth hormone response to growth hormone-releasing hormone in man. Neuroendocrinology 1987 Mar; 45: 243–7PubMedCrossRefGoogle Scholar
  14. 14.
    Jaffe CA, DeMott-Friberg R, Barkan AL. Endogenous growth hormone (GH)-releasing hormone is required for GH responses to pharmacological stimuli. J Clin Invest 1996 Feb 15; 97: 934–40PubMedCrossRefGoogle Scholar
  15. 15.
    Chappel S. Can GHRH or GH secretagogues re-initiate pituitary GH pulsatility. Clin Endocrinol. (In press)Google Scholar
  16. 16.
    Underwood LE, Van Wyk JJ. Normal and aberrant growth. In: Wilson JD, Foster DW, editors. Williams textbook of endocrinology. 8th ed. Philadelphia (PA): WB. Saunders Company, 1992: 1079–138Google Scholar
  17. 17.
    Lindsay R, Feldkamp M, Harris D, et al. Utah growth study: growth standards and the prevalence of growth hormone deficiency. J Pediatr 1994; 125: 29–35PubMedCrossRefGoogle Scholar
  18. 18.
    Shalet SM, Toogood A, Rahim A, et al. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev 1998; 19: 203–23PubMedCrossRefGoogle Scholar
  19. 19.
    Hintz RL. Disorders of growth. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison’s principles of internal medicine. 13th ed. v. 2. New York: McGraw-Hill Inc, 1994: 1918–21Google Scholar
  20. 20.
    Carel J-C, Tresca J-P, Letrait M, et al. Growth hormone testing for the diagnosis of growth hormone deficiency in childhood: a population register-based study. J Clin Endocrinol Metab 1997; 82: 2117–21PubMedCrossRefGoogle Scholar
  21. 21.
    Gaudreau P, Boulanger L, Abribat T. Affinity of human growth hormone-releasing factor (1-29)NH2 analogues for GRF binding sites in rat adenopituitary. J Med Chem 1992 May 15; 35: 1864–9PubMedCrossRefGoogle Scholar
  22. 22.
    Engström G, Lindström P, Sävendahl L. Lack of evidence for acute effects of growth hormone-releasing hormone on serum insulin and glucose levels in normal and hypophysectomized rats. Horm Res 1994; 41(1): 21–6PubMedCrossRefGoogle Scholar
  23. 23.
    Petitclerc D, Pelletier G, Lapierre H, et al. Dose response of two synthetic human growth hormone-releasing factors on growth hormone release in heifers and pigs. J Anim Sci 1987; 65: 996–1005Google Scholar
  24. 24.
    Clark RG, Robinson ICAF. Growth induced by pulsatile infusion of an amidated fragment of human growth hormone releasing factor in normal and GHRF-deficient rats. Nature 1985 Mar 21–27; 314: 281–3PubMedCrossRefGoogle Scholar
  25. 25.
    Grossman A, Savage MO, Lytras N, et al. Responses to analogues of growth hormone-releasing hormone in normal subjects, and in growth-hormone deficient children and young adults. Clin Endocrinol Oxf 1984 Sep; 21: 321–30PubMedCrossRefGoogle Scholar
  26. 26.
    Wilton P, Chardet Y, Danielson K, et al. Pharmacokinetics of growth hormone-releasing hormone(1-29)-NH2 and stimulation of growth hormone secretion in healthy subjects after intravenous or intranasal administration. Acta Paediatr 1993 Mar; Suppl. 388: 10-5Google Scholar
  27. 27.
    Barron JL, Coy DH, Millar RP. Growth hormone responses to growth hormone-releasing hormone (1-29)-NH2 and a D-Ala2 analog in normal men. Peptides 1985 May–Jun; 6: 575–7PubMedCrossRefGoogle Scholar
  28. 28.
    Spoudeas HA, Winrow AP, Hindmarsh PC, et al. Low-dose growth hormone-releasing hormone tests: a dose-response study. Eur J Endocrinol 1994 Sep; 131: 238–45PubMedCrossRefGoogle Scholar
  29. 29.
    Looij Jr BJ, Nieuwenhuijzen-Kruseman AC, Mudde AH, et al. The interaction of growth hormone releasing hormone with other hypothalamic hormones on the release of anterior pituitary hormones. Clin Endocrinol Oxf 1986 Feb; 24: 149–56PubMedCrossRefGoogle Scholar
  30. 30.
    Aitman TJ, Rafferty B, Coy D, et al. Bioactivity of growth hormone releasing hormone (1-29) analogues after SC injection in man. Peptides 1989 Jan–Feb; 10: 1–4PubMedCrossRefGoogle Scholar
  31. 31.
    Ranke MB, Gruhler M, Rosskamp R, et al. Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency. Eur J Pediatr 1986 Dec; 145: 485–92PubMedCrossRefGoogle Scholar
  32. 32.
    Tiulpakov AN, Brook CGD, Pringle PJ, et al. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clin Endocrinol 1995 Sep; 43: 347–50CrossRefGoogle Scholar
  33. 33.
    Thorner M, Rochiccioli P, Colle M, et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. J Clin Endocrinol Metab 1996; 81(3): 1189–96PubMedCrossRefGoogle Scholar
  34. 34.
    Gelander L, Albertsson-Wikland K. Growth hormone (GH) release after administration of GH-releasing hormone in relation to endogenous 24-h GH secretion in short children. J Endocrinol 1989 Jul; 122: 61–8PubMedCrossRefGoogle Scholar
  35. 35.
    Neyzi O, Yordam N, Öcal G, et al. Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone. Acta Paediatr 1993 Mar; Suppl. 388: 16-22Google Scholar
  36. 36.
    Murray FT, Brentzel HJ, Hanson B, et al. Peak growth hormone responses to growth hormone-releasing hormone (GRF 1-29; Geref Diagnostic™, Geref® stimulation in growth hormone deficient children: intravenous versus subcutaneous testing [abstract]. Endocrine Society Meetings; 1998 JunGoogle Scholar
  37. 37.
    Gelato MC, Pescovitz OH, Cassorla F, et al. Dose-response relationships for the effects of growth hormone releasing factor (1-44)NH2 in young adult men and women. J Clin Endocrinol Metab 1984; 59: 197–201PubMedCrossRefGoogle Scholar
  38. 38.
    Pintor C, Fanni V, Loche S, et al. Synthetic hpGRF1-40 stimulates growth hormone and inhibits prolactin secretion in normal children and children with isolated growth hormone deficiency. Peptides 1983; 4: 929–33PubMedCrossRefGoogle Scholar
  39. 39.
    Vance ML, Borges JLC, Kaiser DL, et al. Human pancreatic tumor growth hormone-releasing factor: dose-response relationships in normal man. J Clin Endocrinol Metab 1984; 58: 838–44PubMedCrossRefGoogle Scholar
  40. 40.
    Chen R-G, Shen Y-N, Yei J, et al. Acomparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency. Acta Paediatr 1993 Mar; Suppl. 388: 32–6Google Scholar
  41. 41.
    Rafferty B, Poole S, Clarke R, et al. Growth hormone-releasing factor analogue (hGRF1-29NH2 ): immunoreactive-GRF plasma levels after intravenous and subcutaneous administration. J Endocrinol 1985 Dec; 107: R5–8PubMedCrossRefGoogle Scholar
  42. 42.
    Rafferty B, Coy DH, Poole S. Pharmacokinetic evaluation of superactive analogues of growth hormone-releasing factor (1-29)-amide. Peptides 1988 Jan–Feb; 9: 207–9PubMedCrossRefGoogle Scholar
  43. 43.
    Fernandez-Gonzalez MA, Barrios V, Sancho JI, et al. Tissue and plasma distribution of exogenous growth hormone-releasing factor analogue (GRF1-29NH2 ) after intravenous, subcutaneous and intraperitoneal injection in the rat. Gen Pharmacol 1987; 18: 551–4PubMedCrossRefGoogle Scholar
  44. 44.
    Frohman LA, Downs TR, Heimer EP, et al. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest 1989; 83: 1533–40PubMedCrossRefGoogle Scholar
  45. 45.
    Ghigo E, Bellone J, Aimaretti G, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab 1996; 81: 3323–7PubMedCrossRefGoogle Scholar
  46. 46.
    Ghigo E, Aimaretti G, Gianotti L, et al. New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996; 134: 352–6PubMedCrossRefGoogle Scholar
  47. 47.
    Valetta MR, Bellone J, Baffoni C, et al. Reproducibility of the growth hormone response to stimulation with growth hormone-releasing hormone plus arginine during lifespan. Eur J Endocrinol 1996; 135: 568–72CrossRefGoogle Scholar
  48. 48.
    Colao A, Cerbone G, Pivonello R, et al. The growth hormone (GH) response to the arginine plus GH-releasing hormone terst is correlated to the severity of lipid profile abnormalities in adult patients with GH deficiency. J Clin Endocrinol Metab 1999; 84: 1277–82PubMedCrossRefGoogle Scholar
  49. 49.
    Aimaretti G, Corneli G, Razzore P, et al. Comparison between insulin-induced hypoglycemia and growth hormone (GH-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults. J Clin Endocrinol Metab 1998; 83: 1615–8PubMedCrossRefGoogle Scholar
  50. 50.
    Murray FT, Howard CP, Saenger P, et al. GRF 1-29 (Geref®) therapy accelerates growth in growth hormone-deficient (GHD) children beyond the first year of therapy [abstract no. 463]. Pediatr Res 1998; 43 (Pt 2): 82ACrossRefGoogle Scholar
  51. 51.
    Children’s Mercy Hospital. Treatment with growth hormone releasing hormone shows continued benefits for Gh deficient children as presented at Pediatric Academy Society Annual Meeting [online]. PR Newswire 1998 May 5; [2 pages]. Available from: URL:
  52. 52.
    Serono Laboratories Incorporated. Geref® (sermorelin acetate for injection) prescribing information. Randolph, USA. August 1997Google Scholar
  53. 53.
    Ogilvy-Stuart AL, Stirling HF, Kelnart CJH, et al. Treatment of radiation-induced growth hormone deficiency with growth hormone-releasing hormone. Clin Endocrinol 1997; 46(5): 571–8CrossRefGoogle Scholar
  54. 54.
    Geref* 50. ABPI compendium of data sheets and summaries of product characteristics 1988–99. London: Datapharm Publications Limited: 1294-5Google Scholar
  55. 55.
    US launch of Ares-Serono’s Geref as therapeutic. Marketletter 1998 May 4; 25: 19Google Scholar
  56. 56.
    Serono Geref dose-optimization study should focus on multiple injection effects. FDC Pink 1997 Oct 6; 59: 5–6Google Scholar
  57. 57.
    Cuneo RC, Judd S, Wallace JD, et al. The Australian multicenter trial of growth hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998; 83: 107–16PubMedCrossRefGoogle Scholar
  58. 58.
    Blethen SL, Allen DB, Graves D, et al. Safety of recombinant deoxyribonucleic acid-derived growth hormone: the National Cooperative Growth Study experience. J Clin Endocrinol Metab 1996; 81: 1704–10PubMedCrossRefGoogle Scholar
  59. 59.
    Serono Laboratories Incorporated. Geref® Diagnostic. Prescribing information, Randolph, USA. Revised March 1998Google Scholar
  60. 60.
    American Academy of Pediatrics Committee on Drugs and Committee on Bioethics. Considerations related to the use of recombinant human growth hormone in children. Pediatrics 1997; 99: 122–9CrossRefGoogle Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  1. 1.Adis International LimitedMairangi BayNew Zealand

Personalised recommendations